Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors

Annals of the Rheumatic Diseases

Volumn 71, Issue 12, 2012, Pages

  Mariette, Xavier ^a   Reynolds, Alan Vaughan ^b   Emery, Paul ^c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b Reynolds Clinical Sciences Ltd   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR INHIBITOR;

BASAL CELL CARCINOMA; CANCER REGISTRY; CANCER RISK; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; LETTER; META ANALYSIS (TOPIC); NON MELANOMA SKIN CANCER; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA;

ANTIRHEUMATIC AGENTS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; HUMANS; PROSPECTIVE STUDIES; RHEUMATIC DISEASES; RISK FACTORS; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84868470243     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202478     Document Type: Letter

References (7)

1. Mariette X, Matucci-Cerenic M, Pavelka K, et al. Malignancies associated with TNF inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011;70:1895-904.
2. Mercer LK, Galloway JB, Lunt M, et al. The influence of anti-TNF therapy upon incidence of Non-Melanoma Skin Cancer (NMSC) in patients with rheumatoid arthritis (RA): results from the BSR Biologics Register (BSRBR). Arthritis Rheum 2009;60(Suppl 10):2062.
3. Mercer LK, Green AC, Galloway JB, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012;71:869-74.
4. Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011;20:119-30.
5. Askling J, ARTIS study group. Anti-TNF therapy and risk of skin cancer, data from the Swedish ARTIS registry 1998-2006. Ann Rheum Dis 2009;68(Suppl 3):423.
6. Greenberg J, Strand V, Keystone E, et al. TNF inhibitors (TNF-I) and risk of malignancy in 8, 072 RA patients followed over 15, 495 patient years. Am Coll Rheumatol Annu Meeting 2007;58(Suppl 10);Abstract 282.
7. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95.